2019 Archives | University of Maryland School of Medicine

May 01, 2019 | Centers for Disease Control and Prevention (CDC)

Source: Centers for Disease Control and Prevention (CDC)

The Government of Nigeria, the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR), CDC, and the University of Maryland School of Medicine released new data from the Nigeria HIV/AIDS Indicator and Impact Survey (NAIIS), one of the largest population-based HIV/AIDS household surveys ever conducted. The NAIIS directly measured HIV prevalence and viral load suppression. According to the NAIIS results, the HIV prevalence in Nigeria is lower than previously thought, allowing the country to focus on providing services to the areas of greatest need to control the HIV epidemic.

The NAIIS found that in Nigeria the HIV prevalence – the percentage of people living with HIV in Nigeria – among adults age 15-64 years was 1.5 percent (1.9 percent among females and 1.1 percent among males), and among children age 0-14 was 0.2 percent. HIV prevalence was the highest among females age 35-39 years at 3.3 percent and among males age 50-54 years at 2.3 percent. The disparity in HIV prevalence between females and males was greatest among younger adults, with females age 20-24 years (1.3 percent) having more than three times the prevalence of males in the same age group (0.4 percent).

The NAIIS also found that the prevalence of viral load suppression (VLS), a widely used measure of effective HIV treatment in a population, among all people living with HIV age 15-64 years in Nigeria was 44.5 percent (46.2 percent among females and 40.9 percent among males). The disparity in VLS between females and males was greatest among those age 25-34 years, with females age 25-34 years (40.0 percent) being twice as likely to have VLS compared to males in the same age group (20.3 percent).

The President of Nigeria Muhammadu Buhari released the NAIIS results on March 14. The NAIIS was led by the Government of Nigeria through the Federal Ministry of Health and the National Agency for the Control of AIDS; conducted with funding from the U.S. President’s Emrgency Plan for AIDS Relief and the Global Fund to Fight AIDS, Tuberculosis and Malaria and technical assistance from CDC; and implemented by the NAIIS Consortium, led by the University of Maryland School of Medicine with supervision from the NAIIS Technical Committee. The survey reached more than 250,000 respondents in nearly 100,000 households.

Read the full story at: https://www.cdc.gov/globalhivtb/who-we-are/features/nigeria-phia.html

Contact

Institute of Human Virology
Jennifer Gonzales
Public Relations & Communications Manager
jennifer.gonzales@ihv.umaryland.edu

Centers for Disease Control and Prevention (CDC)
1-800-CDC-INFO (800-232-4636)
TTY: 888-232-6348

Pfizer announced last week that it expects to run out of a key drug for treating syphilis in the near future — a looming problem that health professionals say could exacerbate syphilis rates, widen racial disparities in sexually transmitted diseases, and stymie global access to the antibiotic, especially within lower-income countries. The drug in question is Bicillin, an injectable, long-acting form of penicillin most commonly used to treat syphilis in adults as well as childhood infections.

Monday, June 19, 2023

University of Maryland, Baltimore Leadership Helps IHV-Nigeria Launch State-of-the-Art Campus in Public Healthcare, Treatment Training, and Research in Nigeria

The Institute of Human Virology-Nigeria (IHV-Nigeria), an affiliate of the University of Maryland School of Medicine’s (UMSOM) Institute of Human Virology (IHV), recently announced the launch of its state-of-the-art multi-campus of excellence in public healthcare, treatment training, and research to bring quality health services within the reach of millions of Nigerians.

Thursday, April 27, 2023

Current HIV Research: Milestones: Dr. Robert C. Gallo and the Discovery of HIV-1

In this issue of the journal, we inaugurate a new series entitled “Milestones.” This series will encompass interviews with some of the pioneers that have laid the foundations of HIV research. Revisiting these landmarks while taking into account the prospect of their founders should be an inspiration to our readers, particularly the youngest generation. Nobody better than Dr. Robert Gallo could be the protagonist of the inaugural “Milestone,” with his recount of the discovery of HIV-1, the causative agent of AIDS, and the development of the first blood test to diagnose HIV-1 infection.

Wednesday, January 18, 2023

BBC: The scientist who smuggled HIV in her bag into her country to study it and save lives

Acquired immune deficiency syndrome, AIDS, had been recognized as a new disease in 1981, when an increasing number of young homosexuals died of unusual infections and rare cancers. It was also known to affect intravenous drug users and some were known to have contracted it through blood transfusions.

Friday, January 06, 2023

USA Today: Fact check: Research proves HIV is the cause of AIDS, contrary to viral claim

The claim: There is no proof HIV is the cause of AIDS. A Dec. 15 Facebook video shows Kary Mullis, a scientist known for denying the link between HIV and AIDS, claiming again there is no proof HIV is the cause of AIDS. The post was shared more than 1,000 times in a week. The clip comes from a 2009 documentary that promoted AIDS denialism, which has more than 300,000 views on YouTube.

Wednesday, December 21, 2022

Lead Stories: Fact Check: Doctor Did NOT Say On Video That He Manufactured AIDS As Bio Weapon -- This Is A Soviet-Era Disinformation Hoax

Did an American doctor admit on video that he created the HIV and AIDS viruses in a U.S. military medical laboratory, Fort Detrick, so that they could be used as biological weapons for depopulating the world? No, that's not true: Dr. Robert Gallo, the doctor featured in the video, makes no such admission in the footage, and told Lead Stories that his scientific work was not part of any plan to weaponize HIV/AIDS. Historical records show that the claim is a well-documented hoax that dates to a Soviet disinformation campaign from the 1980s.

Thursday, December 01, 2022

Everyday Health: 10 Facts About HIV/AIDS Everyone Should Know

A basic understanding of HIV and AIDS can help dispel the myths, erase stigma, prevent virus transmission, and save lives — beginning with your own.

Wednesday, September 28, 2022

TheBody: What Is HIV Remission?

A cure for HIV remains elusive, but one word that is commonly heard is “remission.” Even though it doesn’t mean eradication of the virus, remission is a good thing. But what exactly is remission? Can HIV go into remission? And how does it differ from a cure? Generally, remission means that a disease has stopped being active but hasn’t necessarily been eliminated.

Monday, September 19, 2022

TheBody: HIV Seroconversion: Timeline, Symptoms, Testing, and Treatment

There are several stages of HIV infection—from the initial exposure to the virus to the development of AIDS—but a lot of important changes happen during the earliest stage: seroconversion. So, exactly what is HIV seroconversion? It is the stage in which the immune system first starts to make antibodies to try to fight HIV after exposure. Once detectable levels of antibodies are produced, this is described as seroconversion.

Monday, September 19, 2022

TheBody: What Are the Chances of Getting HIV from One Exposure?

You had a one-night stand with someone of questionable HIV status. Now the panic begins. Could you have HIV after only one exposure? What are the odds?

Tuesday, May 31, 2022

Medscape: Fatigue Affects Cognitive Processing Speed in the Aging HIV Population

Successful aging is something that most of us strive for. But with aging comes a pervasive condition called fatigue that, in many older adults, interferes with everyday functioning, mental health, social support, and overall quality of life. The relationship between fatigue and cognitive and functional impairment is one of particular interest in people living with HIV (PWH), a patient population that is disproportionately affected but whose lifespan now matches that of the general population.

Friday, May 20, 2022

NIH Grant Awarded to Study HIV Drug-Resistant Genetic Mutations Across Africa

University of Maryland School of Medicine (UMSOM)’s Institute of Human Virology (IHV) researchers received funding from the National Institutes of Health’s National Institute of Allergy and Infectious Diseases (NIAID) for $2.7 million to study genetic changes in two genes from the HIV-1 virus that may make it resistant to antiretroviral therapy. The study, named INSPIRE, will analyze genetic variation in types of HIV circulating in a handful of African countries that will help to better understand the implications of these mutations and will improve clinical management of patients.

Tuesday, May 10, 2022

Medscape: Decentralizing PrEP Offers a Roadmap for Retention

Good solutions have great roadmaps. For HIV preexposure prophylaxis (PrEP), the road map might just be that of contraceptive care. Once an onerous process, over time contraceptive care exploded into a range of options across a broad landscape in terms of approach and accessibility. How then do organizations help vulnerable patients navigate their PrEP journeys using the contraceptive roadmap as a guide?

Friday, March 18, 2022

Deutsche Presse-Agentur: Virus hunt for decades: US researcher Robert Gallo turns 85

Few scientists in the world can come up with as many successes as Robert Gallo: The US researcher was involved in the discovery of the AIDS virus, found leukemia pathogens and other deadly viruses. Now he is 85 - and works even harder than before.

Thursday, March 10, 2022

Healthline: HIV-1 May Be More Virulent When Transmitted Through Penile-Vaginal Intercourse

HIV-1 can be transmitted through vaginal, anal, and oral sex, whether it’s with a same-sex or different-sex partner. But the risk of developing it seems to vary depending on how the disease is transmitted. In fact, the HIV virus may be more virulent when passed between male and female partners who have penile-vaginal sex than among men who have anal sex with other men, according to a new study from the Indian Institute of Science.

Thursday, March 10, 2022

HIV Plus: One Woman Shares Her Journey of Living with HIV for Over Three Decades

In honoring long-term survivors and National Women and Girls HIV Awareness Day on March 10, I had the opportunity to speak with Ms. Kathy Bennett. She is a 63-year-old Black woman who has been living with HIV for over 31 years. She recently led the longest running HIV support group in Maryland.

Wednesday, February 16, 2022

WBAL: Maryland HIV researcher on latest research: It's not a cure

Scientists used a cutting-edge stem cell transplant method to treat a woman's HIV, but a lead researcher in Maryland said it's too soon to celebrate. A U.S. woman is the third known person who is in HIV remission after receiving stem cells from umbilical cord blood, an American research team announced Wednesday.

Monday, February 07, 2022

The GW Hatchet: University administers first doses of mRNA HIV vaccine through Moderna partnership

GW was one of the first institutions in the country to administer doses of the first mRNA HIV vaccines to human test subjects late last month. The School of Medicine and Health Sciences and its Vaccine Research Unit collaborated with Moderna to test the safety of the vaccine and the immune responses of two participants in the phase 1 clinical trial.

Friday, February 04, 2022

WYPR: How the COVID pandemic rattled HIV testing

The COVID pandemic did not end the HIV-AIDS epidemic; it may have obscured it for a while, raising hurdles to getting tested for HIV.

Wednesday, January 26, 2022

STAT: Early research suggests cancer drug could help flush HIV from its hiding spots

In a study published Wednesday in Science Translational Medicine, researchers looked at 32 patients that had both cancer and HIV and found that pembrolizumab, which revives the immune system and encourages it to attack tumors, also has the ability to flush HIV out of its hiding spot in immune cells.

Wednesday, November 10, 2021

Omaha World-Herald: UNMC researchers develop 'molecular scissors' to target HIV

Researchers at the University of Nebraska Medical Center have used a new method they’re calling a “molecular scissors” to nearly eliminate HIV embedded in the genetic material of human cells.

Tuesday, July 06, 2021

UM School of Medicine Researchers Receive NIH Avant-Garde Award for Out-Of-Box Concept to Cure HIV and Treat Co-Existing Addiction

Linda Chang, MD, MS, Professor of Diagnostic Radiology & Nuclear Medicine at the University of Maryland School of Medicine (UMSOM), received the National Institute on Drug Abuse (NIDA) 2021 Avant-Garde Award (DP1) for HIV/AIDS and Substance Use Disorder Research, a National Institutes of Health (NIH) Director’s Pioneer Award. This prestigious award supports researchers with exceptional creativity, who propose high-impact research with the potential to be transformative to the field. She will work with Institute for Human Virology (IHV) researchers for this project.

Monday, June 07, 2021

POZ: Integrate Adult and Pediatric HIV Care to Ease Youth Transition to Adult Care

Embedding an adult HIV medicine clinician and care navigator into a Baltimore pediatric HIV clinic led to 95% of young people remaining engaged in adult care one year after transition, according to a report in AIDS Care.

Thursday, May 27, 2021

Baltimore Sun: Maryland researchers study whether HIV cure can come from infusing patients with genetically modified ‘super T cells’

A week ago, a Washington, D.C., man in his 30s with HIV became the first person to be infused with a heaping load of his own genetically modified cells that a Maryland biotech firm believes one day could lead to the elusive cure for the disease. American Gene Technologies’ method involves taking T cells out of a person’s blood and genetically modifying them in the lab to resist infection before they are reinfused. C. David Pauza is the company’s chief science officer and a former professor and researcher at the University of Maryland School of Medicine’s Institute for Human Virology. Another center evaluating entering the study is Maryland’s Institute for Human Virology, confirmed its co-founder and director, Dr. Robert Gallo, who is internationally regarded for his role in discovering HIV and developing a blood test to detect it.

Thursday, April 01, 2021

A Statement from the Leadership of the University of Maryland School of Medicine’s Institute of Human Virology on the Passing of Dr. John Martin

The Institute of Human Virology at the University of Maryland School of Medicine mourns the passing of IHV 2014 Lifetime Achievement Public Service Awardee and 2017 Annual Marlene and Stewart Greenebaum Lecturer, John Martin, PhD. Dr. Martin was a leader in supporting access to life-saving anti-HIV medications that although still under patent were made widely and affordably available to millions around the world infected with HIV, and for prevention through pre-exposure drug therapy. He was a tremendous clinical scientist, businessman, global public health leader, philanthropist, and good friend.

Monday, August 03, 2020

Infectious Disease Special Edition: COVID-19 and HIV: Was It a Deadly Mix?

Social distancing is one of the curses of COVID-19, and may fall more heavily on people with HIV than on those without this burden. “People with HIV, and in particular certain subsets of that group—the LGBTQ community, older adults aging with HIV, etc.—face more mental health issues than the general population,” said Sarah Schmalzle, MD, an assistant professor of medicine at the Institute of Human Virology, University of Maryland School of Medicine, in Baltimore. “Many of our patients also already face significant isolation and loneliness due to a combination of HIV stigma, losses of friends and family to HIV, and aging.”

Tuesday, July 07, 2020

Courthouse News Service: Global Progress on Ending HIV/AIDS Derailed by Covid-19

A United Nations program aimed at eliminating HIV/AIDS released a report Monday showing that the global response to the epidemic has fallen far short of goals set for 2020, in large part due to the coronavirus pandemic.

Tuesday, June 02, 2020

UM School of Medicine’s Institute of Human Virology Awarded Grants to Strengthen COVID-19 Response in Sub-Saharan Africa

The Center for International Health, Education and Biosecurity (Ciheb) at the University of Maryland School of Medicine’s Institute of Human Virology was awarded $4 million from the U.S. Centers for Disease Control and Prevention (CDC) to support coronavirus disease 2019 (COVID-19) response activities in Botswana, Nigeria, Malawi, and Mozambique.

Monday, June 24, 2019

UM School of Medicine's Institute of Human Virology Awarded $40 Million Grant to Conduct HIV Population Surveys

Man Charurat, MD, Professor of Medicine, Director, Center for International Health, Education, and Biosecurity (CIHEB), and Director, Division of Epidemiology and Prevention, Institute of Human Virology (IHV) at the University of Maryland School of Medicine (UMSOM), has been awarded a five-year grant from the U.S. Centers for Disease Control and Prevention (CDC) to conduct HIV population-based HIV impact assessments worldwide to measure the progress towards the control of the HIV epidemic

Wednesday, August 02, 2017

UM School of Medicine Receives $2 Million Grant for HIV Research in Malawi

The University of Maryland School of Medicine’s (UM SOM) Institute for Global Health (IGH) and the Institute of Human Virology (IHV) have been awarded a $2 million five-year grant from the Eunice Kennedy Shriver National Institute of Child Health and Human Development to study the impact exposure to HIV has on the immune systems of infants in utero and how those changes impact the ability of infants to fight off infections after birth.

Tuesday, October 25, 2016

"A Call to End HIV/AIDS in America" IHV Director Dr. Robert Gallo's Op-Ed in the Huffington Post

As the new Administration is presented with great challenges facing the United States, one will be a longtime foe, the U.S. HIV/AIDS epidemic. Since President Barack Obama was elected in 2008, I have publicly called on our country’s leaders to utilize the largest global health initiative in history - the President’s Emergency Plan for AIDS Relief (PEPFAR) - as a model to address the U.S. epidemic.

Large National Survey Shows Smaller HIV Epidemic in Nigeria Than Once Thought and Highlights Key Gaps